How big is the Short-acting Insulin Market?

The Short-acting Insulin Market size is expected to reach USD 7.23 billion in 2024 and grow at a CAGR of 3.46% to reach USD 8.58 billion by 2029. Read More

What is the current Short-acting Insulin Market size?

In 2024, the Short-acting Insulin Market size is expected to reach USD 7.23 billion. Read More

Who are the key players in Short-acting Insulin Market?

Eli Lilly, Sanofi Aventis, Novo Nordisk AS, Pfizer and Biocon are the major companies operating in the Short-acting Insulin Market. Read More

Which is the fastest growing region in Short-acting Insulin Market?

Middle-East and Africa is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Short-acting Insulin Market?

In 2024, the North America accounts for the largest market share in Short-acting Insulin Market. Read More

What years does this Short-acting Insulin Market cover, and what was the market size in 2023?

In 2023, the Short-acting Insulin Market size was estimated at USD 6.98 billion. The report covers the Short-acting Insulin Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Short-acting Insulin Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Short-acting Insulin Market Share

Statistics for the 2023 & 2024 Short-acting Insulin market share, created by Mordor Intelligence™ Industry Reports. Short-acting Insulin share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Short-acting Insulin Industry

The Short-Acting Insulin Market is highly consolidated, with leading companies like Sanofi, Novo Nordisk, and Eli Lilly, having a strong market presence. Each of these companies has established its brands in the market. However, due to intense competition in the local markets, these manufacturers put a lot of effort into penetrating these markets. Hence, they employ powerful competitive strategies to improve their foothold in the market. Additionally, the high profitability of the market provides an incentive for several generic insulins (biosimilars) manufacturers and major companies trying to introduce innovative products.